Lanean...
Practical management of patients with myelofibrosis receiving ruxolitinib
Myelofibrosis (MF) is characterized by bone marrow fibrosis, progressive anemia and extramedullary hematopoiesis, primarily manifested as splenomegaly. Patients also experience debilitating constitutional symptoms, including sequelae of splenomegaly, night sweats and fatigue. Ruxolitinib (INC424, IN...
Gorde:
| Argitaratua izan da: | Expert Rev Hematol |
|---|---|
| Egile Nagusiak: | , , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2013
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8201600/ https://ncbi.nlm.nih.gov/pubmed/24083419 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1586/17474086.2013.827413 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|